Atopic Dermatitis: Clinical Trials

35 trials for Atopic Dermatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 terminated. 35 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 235Terminated 35
Phase 14Terminated 4
Phase 32Terminated 2

Follow Atopic Dermatitis: new trials by email Literature Review of Atopic Dermatitis trials Research Report on Atopic Dermatitis

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
Dupilumab, Placebo, IBI356 - Atopic Dermatitis
Phase 2TerminatedInnovent Biologics (Suzhou) Co. Ltd.182025-12-312026-10-27
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
SAR444656 (KT-474), Placebo - Atopic Dermatitis
Phase 2TerminatedSanofi702023-11-092026-11-03
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Phase 1 / Phase 2TerminatedInmagene LLC132023-08-092025-11-06
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
LY3454738, Placebo - Atopic Dermatitis
Phase 2TerminatedEli Lilly and Company2342023-06-212025-12-02
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified
Phase 2 / Phase 3TerminatedPfizer582023-01-182025-05-08
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
BMX-010, Placebo - Atopic Dermatitis
Phase 2TerminatedBioMimetix JV, LLC1032023-01-082024-04-18
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
AK002, Placebo - Atopic Dermatitis
Phase 2TerminatedAllakos Inc.1312022-06-272024-10-15
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation
Application of Tralokinumab - Atopic Dermatitis
Phase 2 / Phase 3TerminatedUniversity of Zurich242022-06-152026-02-06
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
RPT193, Placebo - Atopic Dermatitis
Phase 2TerminatedRAPT Therapeutics, Inc., a member of the GSK plc group of companies2292022-06-072026-03-23
A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials
EDP1815 - Atopic Dermatitis
Phase 2TerminatedEvelo Biosciences, Inc.2872022-06-062023-09-07
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Broncho-Vaxom, Placebo - Atopic Dermatitis
Phase 2TerminatedOM Pharma SA632021-12-202023-08-08
Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel
DBI-001, Aqueous gel - Atopic Dermatitis
Phase 2TerminatedDermBiont, Inc.102021-10-062023-11-08
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Placebo, AK120 - Atopic Dermatitis
Phase 2TerminatedAkesobio Australia Pty Ltd792021-09-302025-02-26
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
FB-401 - Atopic Dermatitis
Phase 2TerminatedForte Biosciences, Inc.362021-06-022021-10-28
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
Benralizumab, Placebo / Benralizumab - Atopic Dermatitis
Phase 2TerminatedAstraZeneca1942020-11-122023-08-31
Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
DS107, Placebo - Atopic Dermatitis
Phase 2TerminatedDS Biopharma2192019-09-192022-11-28
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
Clobetasol propionate 0.05% Topical Oil - Atopic Dermatitis
Phase 1 / Phase 2TerminatedHill Dermaceuticals, Inc.82019-09-092021-06-23
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
J. lividum - Atopic Dermatitis
Phase 2TerminatedDermBiont, Inc.92019-05-202021-06-18
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
ZPL389 30mg, ZPL389 50mg, TCS and/or TCI - Atopic Dermatitis
Phase 2TerminatedNovartis Pharmaceuticals1232019-04-042021-10-08
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
MOR106, Placebo - Atopic Dermatitis
Phase 2TerminatedLakefront Biotherapeutics NV332019-03-252021-01-05

Showing 20 of 35. Sign in to see all of them.

Narrower conditions

Dermatitis, Atopic (35)  ·  Eczema (10)  ·  Dermatitis (6)  ·  Pruritus (4)  ·  Lymphoma, Follicular (3)  ·  Skin Diseases (3)  ·  Immune System Diseases (2)  ·  Alopecia (1)  ·  Inflammation (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Mycosis Fungoides (1)  ·  Psoriasis (1)  ·  Skin Diseases, Eczematous (1)  ·  Staphylococcal Infections (1)  ·  Striae Distensae (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (35)  ·  Genetic Diseases, Inborn (35)  ·  Hypersensitivity (35)  ·  Hypersensitivity, Immediate (35)  ·  Skin Diseases, Genetic (35)  ·  Skin and Connective Tissue Diseases (35)  ·  Skin Diseases, Eczematous (34)  ·  Immune System Diseases (33)  ·  Skin Diseases (32)  ·  Dermatitis (29)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Signs and Symptoms (5)  ·  Skin Manifestations (5)  ·  Hemic and Lymphatic Diseases (4)  ·  Immunoproliferative Disorders (4)

Interventions

dupilumab (2)  ·  itepekimab (2)  ·  8,11,14-Eicosatrienoic Acid (1)  ·  AK002 (1)  ·  BANG polymer gel (1)  ·  Broncho-Vaxom (1)  ·  Clobetasol (1)  ·  Oils (1)  ·  Therapeutics (1)  ·  antroquinonol (1)  ·  benralizumab (1)  ·  etrasimod (1)  ·  gusacitinib (1)  ·  halobetasol (1)  ·  tezepelumab (1)

Sponsors

Regeneron Pharmaceuticals (3)  ·  DermBiont, Inc. (2)  ·  Eli Lilly and Company (2)  ·  Lakefront Biotherapeutics NV (2)  ·  Novartis Pharmaceuticals (2)  ·  Akesobio Australia Pty Ltd (1)  ·  Allakos Inc. (1)  ·  Amgen (1)  ·  Asana BioSciences (1)  ·  AstraZeneca (1)  ·  BioMAS Ltd (1)  ·  BioMimetix JV, LLC (1)  ·  Celsus Therapeutics PLC (1)  ·  Chung Shan Medical University (1)  ·  DS Biopharma (1)

Countries

United States (25)  ·  Poland (14)  ·  Germany (13)  ·  Canada (11)  ·  Czechia (7)  ·  Hungary (6)  ·  Japan (6)  ·  Spain (6)  ·  Australia (5)  ·  South Korea (5)  ·  United Kingdom (5)  ·  Taiwan (4)  ·  Austria (3)  ·  Belgium (3)  ·  Finland (3)

Top investigators

Alex Zvulunov, Prof (1)  ·  Avner Shemer, Prof (1)  ·  Ben Ehst, PhD (1)  ·  Chin Lee, MD, MPH (1)  ·  Daisy Blanco, MD (1)  ·  Dalia Gilat, Dr. (1)  ·  David Zammit, Ph.D. (1)  ·  Douglas Maslin, MD (1)  ·  Eli Sprecher, Prof (1)  ·  Emma Guttman, MD, PhD (1)  ·  Felix Pavlotsky, MD (1)  ·  Franziska Rueff, Professor (1)

Results publications

PMID 39077906, PMID 18645136

NIH funding

2018 (5), 2017 (1), 2023 (1)